Immune checkpoint inhibitors (ICIs) have made significant progress in the treatment of many malignant tumors; however, their efficacy remains limited by the complex immune-suppressive characteristics of the tumor microenvironment (TME), with only a subset of p... ...

请注册登录后继续浏览